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Apomorphine hydrochloride is used to treat refractory motor fluctuations in advanced Parkinson’s disease.
Delivery by infusion is associated with the formation of hard subcutaneous nodules, which may be painful, limit
available infusion sites, and interfere with absorption of the drug. Diagnostic ultrasound was used to image
affected tissue in 12 people experiencing apomorphine nodule formations. It revealed significant departures from
normality in dermal and subcutaneous tissue, including a variety of nodule appearances, dermal thickening and
diffuse changes consistent with inflammatory reactions. Sonographic appearances differed markedly between
individuals, but no clear correlation between severity of tissue changes, patient demographics and apomorphine
dose was observed. Diagnostic ultrasound may be useful as a non-invasive method of assessing subcutaneous
nodule formation, to measure changes in affected tissue over time and after treatment.
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Introduction
The drug apomorphine has been licensed for use in the
United Kingdom since 1993 (Britannia Pharmaceuticals,
Redhill, Surrey, UK). It is a dopamine agonist used for
reducing unpleasant dyskinesias in people with advanced
Parkinson’s disease.1 Those who experience the greatest
motor fluctuations, or debilitating, unpredictable ‘on–off’
periods, receive apomorphine subcutaneously via a contin-
uous pump infusion normally during waking hours. The
infusion site is usually the lower abdomen or upper thigh,1,2
and it is recommended that a new site for needle location is
found each morning.3
The drug has common side-effects including nausea,
confusion, sedation and cutaneous complications.1,2 Over
time, the majority of people infusing apomorphine will
develop painful hard nodules in and around the multiple
injection sites.2,4,5 These painful nodules not only restrict
patient choice of infusion site but may sometimes cause
erratic absorption of the drug.1,4 The development of
subcutaneous complications has been observed also in
people with diabetes mellitus and in some sickle cell
anaemia patients requiring regular intramuscular injections
for pain control.6,7
Few studies have been conducted on the formation of
apomorphine nodules and consequently, little is known about
their aetiology or natural history.4,8 In this exploratory study,
diagnostic ultrasound was used to characterise and catalogue
the appearance of nodules in 12 patients. The study preceded
an investigation into the effectiveness of a novel treatment
strategy for such nodules, with ultrasonographic appearance
being used as an outcome measure.
Method
Ethical approval for this exploratory study using ultrasound,
and for a proposed therapeutic trial, was obtained from the
hospital trust ethics committee. Written informed consent was
obtained from all participants. Twelve patients who used a
continuous apomorphine pump infusion were recruited from a
specialist Parkinson’s disease clinic. Eight were female and
four were male. Ages ranged from 47 to 75 years (mean age
64 years). The mean body mass index was 25.8 (range: 19.1–
36.4). The number of years since Parkinson’s disease was
formally diagnosed ranged from 9 to 32 (mean 20 years).
Apomorphine had been used by the participants for a mean
average of four years (range: 3 months to 10 years) and the
dose rate varied between 3.5 and 13.8 mgh21.
The lower abdomen or upper thigh used for infusing was
palpated manually to identify regions with the most profuse
nodule formation. The affected tissue was photographed and
then imaged by an experienced sonographer using a Sonosite
MicroMaxx unit (Sonosite, Hitchin, UK) with colour Doppler
and a 13–6 MHz linear array transducer.
The depth of field was kept constant at 4 cm. The high
resolution option with compound imaging was employed for
maximum image quality. Images of the affected areas were
acquired in both longitudinal and transverse planes. Control
views of an area nearby which was not used for infusing were
retained for comparison. Images were saved and stored for
later analysis by the sonographer.
Soft copy images were scrutinised for both diffuse and focal
subcutaneous and dermal changes. Normal subcutis has a
uniform hypoechoic appearance and is traversed by thin
septa (Fig. 1).9,10 Non-uniformity of the subcutis indicated the
presence of nodules. Normal dermis is hyperechoic compared
to the subcutis, with an even depth of 2 mm or less (Fig. 1).11
The boundary between normal dermis and subcutis is clearly
delineated on ultrasound. In this study, the dermis was
examined for thickness, uniformity, and boundary demarcation
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from the subcutis. The subcutis was assessed for echogenicity
compared to the control zones, and focal nodular areas within
the subcutis were assessed for size, shape, edge definition,
and echo-texture. Vascularity of the nodular areas was
investigated using colour Doppler on a low velocity setting of
3 cms21.
Results
All the control zones displayed normal dermal and subdermal
sonographic appearances. In the areas used for infusion the
dermis was thickened (3–8 mm) in 42% (n55) of the patients
(Fig. 2), and the boundary between the dermis and subcuta-
neous layer was indistinct in 50% (n56) (Fig. 3). When
compared to control areas not used for infusion, the
subcutaneous layer was diffusely hyperechoic in 42% (n55)
(Fig. 4a). In some cases these diffuse appearances correlated
well with visible inflammatory changes on the skin surface
(Fig. 4b).
From the cohort of twelve patients, 18 nodules were
identified and analysed in detail. The majority were spherical
or fusiform in shape, ranging from 3 to 30 mm in diameter.
Most nodules (61%, n511) had well-defined borders. Seven
(39%) were irregular or indistinct in outline. Four (22%) nodules
were hypoechoic compared to the surrounding subcutis
(Fig. 5). Seven (39%) were isoechoic or hyperechoic com-
pared to the surrounding subcutis (Fig. 6a and b). Isoechoic
nodules were identified by the presence of a hypoechoic halo.
Seven nodules (39%) were truly cystic in appearance (Fig. 7).
One participant who had been using apomorphine in excess
of 10 years demonstrated strongly shadowing linear foci in
addition to having diffuse dermal and subdermal changes
(Fig. 8). Multiple nodules within the same patient often had
varying appearances. None of the 18 focal areas displayed
any detectable vascularity on colour Doppler interrogation.
There was no obvious correlation between patient demo-
graphics, drug dose and severity of nodule formation or other
tissue changes.
Discussion
Ultrasound has been used to examine the skin and sub-
cutaneous layer for over 30 years and is now the imaging
modality of choice due to its ability to achieve high resolution
images and accurate reproducible measurements.9,12–14
Numerous studies have used ultrasound to described a range
of superficial focal and diffuse skin appearances including
tumour, lipoma, haematoma, lymphoma, abscess, cellulitis
and panniculitis.9,10,13–16
We used ultrasound to investigate subcutaneous appear-
ances in people using apomorphine infusions and found that
in every case the infusion sites had markedly abnormal
sonographic appearances compared to control areas. Focal
and/or diffuse subdermal changes were observed in all
patients. Many had dermal thickening and a loss of definition
of the dermis/subcutis boundary. Diffuse hyperechoic appear-
ances and indistinct delineation between dermis and subcutis
are consistent with cellulitis.9,14,17 These observations indicate
that apomorphine infusion is associated with more extensive
changes in tissue than has previously been reported.
A number of causal processes are possible. Tissue changes
may be the consequence of inflammatory effects caused by
repeated needle insertion in a relatively small area.8,18
Associated haemorrhage through repeated needle trauma
can lead to vascular compromise of the capillaries, which also
influences subcutaneous appearances.6,9,19 Although colour
Doppler did not reveal the presence of fine vessels in this
study, power Doppler might have.
Figure 1. Normal abdominal dermis and subcutis.
Figure 2. Thickened dermis and mildy hyperechoic subcutis.
Figure 3. Indistinct dermal-subdermal boundary.
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Traumatic panniculitis cannot be the only mechanism
involved since nodule formation may occur after just one
needle insertion in some patients. Nodule formation could also
be triggered by subcutaneous tissue reacting to the drug itself
or to its preservative. This is supported by evidence that
nodule development is reduced when the drug is diluted with
saline.1 Tissue changes may therefore be a combination of
needle trauma and reaction to the drug compound.
Panniculitis is a complex condition involving inflammation of
the subcutaneous layer beneath the dermis,20 which may
result in fat necrosis.6 Different histopathological appearances
are observed at different stages of panniculitis.20 Injecting
drugs and performing needle biopsies is known to cause
traumatic panniculitis and fat necrosis.9,19,21–23 The appear-
ance of fat necrosis has been described most frequently in the
breast where it can mimic cancer.19,21,24 Other studies report
examples of fat necrosis in the thigh,6,9 and in the abdomen of
a person with diabetes mellitus.7 These nodules were also
tender and resulted in erratic absorption of insulin.
Localised fat necrosis has varying sonographic appear-
ances,9 depending on age,19,21,24 and presence of haemor-
rhage within the fat necrosis,6,19 although it is difficult to
differentiate between the two processes using ultrasound
alone.21,24 This may explain why a wide range of nodular
appearances was seen in our study. Hyperechoic and
hypoechoic foci in apomorphine users may represent not only
nodules of different ages but also regions of fat necrosis mixed
with varying degrees of haemorrhage. The truly cystic nodules
observed may be in keeping with the evolution of old liquefied
haematomata.25,26
Fibrotic changes in breast tissue cause acoustic shadowing
on ultrasound.27 Strong shadowing seen in the subcutis of one
participant in this study may also represent fibrotic tissue
changes, especially in view of the length of time that person
had been infusing apomorphine. Further studies on other long-
term users are needed to investigate this suggestion.
Figure 4. (a) Sonographic image of hyperechoic subcutis of the same patient. (b) Photograph of abdomen with apomorphine infusion in situ.
Appearances suggest cellulitis and nodular formation.
Figure 5. Hypoechoic nodule directly inferior to the dermis.
Figure 6. (a) Isoechoic nodule with hypoechoic border. (b) Hyperechoic nodule (normal dermis).
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Histological correlation with sonographic findings is neces-
sary before any of these interpretations can be verified.
Nevertheless our findings suggest that diagnostic ultrasound
may provide a feasible outcome measure for tracking
subcutaneous tissue changes. The data from this study will
form the foundation for a follow-up study on response of these
lesions to therapeutic ultrasound treatment.
Currently, there is limited evidence regarding prophylaxis or
treatment of apomorphine nodules. Scrupulous hygiene when
preparing to inject, massage of the affected areas, application
of tea tree oil, silicone gel patches, and therapeutic ultrasound
have all been suggested as measures to minimise nodule
formation and hardness.1,2,4 A clearer understanding of
nodule development and appearance is likely to help evaluate
preventative measures and therapeutic pathways. While
histology remains the gold standard in diagnosing and
measuring subcutaneous tissue changes such as panniculitis,
ultrasound has the advantage of being non-invasive, portable,
reproducible and dynamic. Diagnostic ultrasound could have
a role in the tracking of inflammatory changes and may prove
to be a useful imaging modality for assessing the effectiveness
of treatment strategies.28 Recommendations for further work
include correlation of sonographic and histological findings, as
well as tracking the evolution and resolution of nodules in a
large cohort so that risk factors and prognostic indicators may
be identified.
Conclusion
In this study, there was a marked departure from normal in the
sonographic appearances of skin and subcutaneous areas
used for infusing apomorphine. The wide range of nodule
appearances may be due to varying stages of inflammatory
changes associated with the complex process of panniculitis.
Diagnostic ultrasound may be helpful for tracking the evolution
of apomorphine nodules and other changes in surrounding
tissue.
Acknowledgements
The authors gratefully acknowledge the support of SonoSite
UK Limited for supplying a MicroMaxx ultrasound system for
this work. We also extend our thanks to the participants for
taking part in this study, and to Professor Tim Watson,
University of Hertfordshire, the research project lead.
References
1. Lees A, Turner K. Apomorphine for Parkinson’s disease. Practical
Neurology 2002;2:280–286.
2. Bowron A. Practical considerations in the use of apomorphine
injectable. Neurology 2004;62:S32–S36.
3. James CR, Quinn NP, Lees AJ, Swinn LA. Parkinson’s disease
and apomorphine. A guide for patients and those who care for
them. University College London Hospitals NHS Foundation
Trust, 2005.
4. Manson A, Hanagasi H, Turner K, et al. Intravenous apomorphine
therapy in Parkinson’s disease. Clinical and pharmacokinetic
observations. Brain 2001;124:331–340.
5. Pollak P, Benabid A, Limoson P, Jeanneau-Nicolle E. External
and implanted pumps for apomorphine infusion in Parkinsonism.
Acta Neurochir Supplement Wien 1993;58:48–52.
6. Fernando R, Somers S, Edmonson R, Sidhu PS. Subcutaneous
fat necrosis. Hypoechoic appearance on sonography. J
Ultrasound Med 2003;22:1387–1390.
7. Wallymahmed M, Littler P, Clegg C, Haqqani MT, MacFarlane IA.
Nodules of fibrocollagenous scar tissue induced by subcuta-
neous insulin injections: a cause of poor diabetic control.
Postgrad Med J 2004;80:732–733.
8. Acland K, Churchyard A, Fletcher C, Turner K, Lees A, Dowd PM.
Panniculitis in association with apomorphine infusion. Br J
Dermatol 1998;138:480–482.
9. Sidhu P, Rich P. Sonographic detection and characterization of
musculoskeletal and subcutaneous tissue abnormalities in sickle
cell disease. Br J Radiol 1999;72:9–17.
10. Ulrich J, Voit, C. Ultrasound in dermatology. Part II. Ultrasound of
regional lymph node basins and subcutaneous tumours. Eur J
Dermatol 2001;11:73–79.
11. Moore T, Lunt M, McManus B, Anderson ME, Herrick AL.
Seventeen-point dermal ultrasound scoring system – a reliable
measure of skin thickness in patients with systemic sclerosis.
Rheumatology 2003;42:1559–1563.
12. Goldberg B. Ultrasonic evaluation of superficial masses. J Clin
Ultrasound 1975;3:91–94.
Figure 8. Strong acoustic shadowing from reflective foci (with thickened
dermis).
Figure 7. Anechoic or cystic focus (with thickened dermis and indistinct
boundary).
158
Edwards et al. Sonographic Characterisation of Apomorphine Nodules
13. Nessi R, Betti R, Bencini P, Crosti C, Blanc M, Uslenghi C.
Ultrasonography of nodular and infiltrative lesions of the skin and
subcutaneous tissues. J Clin Ultrasound 1990;18:103–109.
14. Beggs I. Ultrasound of soft tissue masses. Imaging
2002;14:202–208.
15. Loyer E, DuBrow R, David C, Coan JD, Eftekhari F. Imaging of
superficial soft tissue infections: sonographic findings in cases of
cellulitis and abscess. Am J Roentgenol 1996;166:149–152.
16. Wortsman X, Holm E, Wulf H, Jemec GB. Real-time spatial
compound ultrasound imaging of skin. Skin Research &
Technology 2004;10:23–31.
17. Loyer E, Kaur H, David C, DuBrow R, Eftekhari FM. Importance of
dynamic assessment of the soft tissues in the sonographic
diagnosis of echogenic superficial abscesses. J Ultrasound Med
1995;14:669–671.
18. van Laar T, van Hilten B. The role of EDTA in provoking allergic
reactions to subcutaneous infusion of apomorphine in patients
with Parkinson’s disease. J Neurol 1998;251:1370–1374.
19. Soo M, Kornguth P, Hertzberg B. Fat necrosis in the breast:
sonographic features. Radiology 1998;206:261–269.
20. Cascajo C, Borghi S, Weyers W. Panniculitis: Definition of terms
and diagnostic strategy. Am J Dermatopathol 2000;22:530–549.
21. Bilgen G, Ustun E, Memis A. Fat necrosis of the breast: clinical,
mammographic and sonographic features. Eur J Radiol
2001;39:92–99.
22. Fo¨rstro¨m L, Winkelmann R. Factitial panniculitis. Arch Dermatol
1974;110:747–750.
23. Patterson J. Differential diagnosis of panniculitis. Adv Dermatol
1991;6:309–329.
24. Chala L, de Barros N, de Camargo Moraes P, et al. Fat necrosis
of the breast: mammographic, sonographic, computed tomo-
graphy and magnetic resonance imaging findings. Curr Probl
Diagn Radiol 2004;33:106–126.
25. Bates J. Abdominal Ultrasound, how why & when. 2nd edn.
Edinburgh: Churchill Livingstone, 2004;84, 187.
26. Wilson D, McLardy-Smith P, Woodham C, MacLarnon JC.
Diagnostic ultrasound in haemophilia. J Bone Joint Surg Br
1987;69B:103–107.
27. Baillie M, Mok P. Fat necrosis in the breast: review of the
mammographic and ultrasound features, and a strategy for
management. Australas Radiol 2004;48:288–295.
28. Chan V, Soans B, Mathers D. Ultrasound and magnetic
resonance imaging features in a patient with eosinophilic
fasciitis. Australas Radiol 2004;48:414–417.
159
ULTRASOUND N August 2008 N Volume 16 N Number 3
